Please login to the form below

Not currently logged in
Email:
Password:

DPP-4 inhibitors

This page shows the latest DPP-4 inhibitors news and features for those working in and with pharma, biotech and healthcare.

FDA won't add outcomes data to Januvia label

FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying ... The DPP-4 inhibitors as

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    around £475 per year and are as cost-effective as DPP-4 inhibitors. ... Technology Evaluation, noting that SGLT2 inhibitors are now "an alternative to the separate group of drugs called DPP-4 inhibitors".

  • Merck drops once-weekly diabetes drug in US and EU Merck drops once-weekly diabetes drug in US and EU

    There are thought to be other issues with once-weekly administration of DPP-4 inhibitors. ... While they are intended to reduce the burden of taking pills by diabetics and improve compliance, patients can rarely benefit from drug-free days as those on DPP

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    DPP-4 inhibitors are already widely used in diabetes and SGLT2 inhibitors are fast gaining ground, despite some initial concerns about safety. . ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney,

  • Merck gets first OK for once-weekly DPP-4 inhibitor Merck gets first OK for once-weekly DPP-4 inhibitor

    and showed that the drug is as effective at controlling blood glucose as daily DPP-4 inhibitors. ... Not all are convinced of the benefit of this approach however, particularly as most patients taking DPP-4 inhibitors also take metformin.

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2013 Pharma deals during April 2013

    standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin. ... SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics